Latest news with #SamiraParhizkar
Yahoo
9 hours ago
- Health
- Yahoo
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
A drug used to treat insomnia has protected mice against the buildup of the tau protein found to clump abnormally in neurodegenerative diseases like Alzheimer's. This could lead to new ways to help slow the progress of these diseases. An increasing number of people are facing cognitive decline personally or in their loved ones. There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still few treatment options that provide clear benefits. So due to the links between Alzheimer's and poor sleep, Washington University neurologist Samira Parhizkar and colleagues investigated a central nervous system depressant, lemborexant, that was approved for use as a sleep aid by the FDA in December 2019. "We have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer's and several related disorders," explains Washington University neurologist David Holtzman. The role of amyloid beta proteins in Alzheimer's has been controversial, but they're not the only proteins implicated in the disease. Tau proteins normally contribute to the structure of brain cells, but past research has linked abnormal ones with the rate of brain atrophy in animal models. "The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer's dementia are helpful, but they don't slow the disease down as much as we would like," says Holtzman. "We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further." But when the researchers compared lemborexant with another sleep aid, zolpidem, the results were unexpected. Mice receiving lemborexant retained up to 40 percent more volume in their memory-forming hippocampus than those who received zolpidem or no sleep aid at all. "What was surprising was that these effects were not seen with a standard sleep drug like zolpidem, which increases NREM sleep similarly to lemborexant," Parhizkar told Eric Dolan at PsyPost. "This suggests that the benefit is not just about more sleep, but rather how that sleep is promoted." The two sleep drugs work on different mechanisms, and that seems to be key to the protective effects. Lemborexant blocks orexin, a neuropeptide that regulates the sleep cycle, and when the team genetically knocked out orexin receptor 2 in mice, it reduced the buildup of tau in their brains. Strangely, though, the protective results of lemborexant were only seen in male mice, even though females were also tested. What's more, mouse studies don't always produce the same results in humans. Lemborexant has only been approved for short-term use in humans, so its long-term impacts as well as effectiveness in tau reduction still need to be investigated. While many questions remain to be answered, if the results seen in this study hold true, the researchers hope early intervention with a drug like lemborexant could potentially delay the progression of neurodegeneration. This research was published in Nature Neuroscience. Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach
Medical News Today
04-06-2025
- Health
- Medical News Today
Alzheimer's: Common insomnia treatment may prevent brain damage
Common insomnia treatment may prevent Alzheimer's-related brain damage, an animal study suggests. Image credit: ljubaphoto/Getty Images. As many as 70 million people around the world live with a sleep disorder. Sleep disorders can impact a person's risk for several health conditions, including dementia and Alzheimer's disease. A new study has found that a medication commonly used to treat insomnia may not only improve sleep quality, but also protect the brain from a buildup of the protein tau, via a mouse model. 'Poor sleep quality and sleep disorders often appear years before other symptoms of dementia due to Alzheimer's disease and related disorders become apparent,' David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology and scientific director of the Hope Center for Neurological Disorders at the Washington University School of Medicine told Medical News Today . He is the senior author of a new study published in the journal Nature Neuroscience , which has found, via a mouse model, that a medication commonly used to treat insomnia may not only improve sleep quality, but also protect the brain from a buildup of the protein tau. For this study, researchers focused on a sleep disorder medication called lemborexant, sold under the brand name Dayvigo. 'Lemborexant belongs to a class of sleep medications called dual orexin receptor antagonists,' Samira Parhizkar, PhD, instructor at Washington University School of Medicine, and first author of this study, explained to MNT . 'These drugs work by blocking orexin — a protein in the brain that keeps us awake and alert.' 'By blocking the orexin signaling, the medication allows sleep to occur quickly and more easily,' Parhizkar continued. 'In other words, if your brain is like a light switch that keeps flicking on when you are trying to sleep, lemborexant helps turn that switch off, so your brain and body gets the rest it needs.' Scientists used lemborexant to treat a model of mice that were genetically prone to having tau buildup in the brain. 'In the healthy brain, tau protein acts as a 'track' that helps support the shape of cells and helps move nutrients and signals where they need to go,' Holtzman detailed. 'In Alzheimer's and a group of neurodegenerative disorders primarily affected by abnormal tau called tauopathies, abnormal tau loses its shape, integrity and therefore cellular functionality leading to tau tangles. The progressive build of these tau tangles leads to nerve cell death that contributes to memory loss, confusion among other cognitive symptoms of Alzheimer's disease,' he explained. At the study's conclusion, researchers found treating the mice with lemborexant helped to prevent the buildup of tau in the brain, reducing the inflammatory brain damage that tau buildup is known to cause in Alzheimer's disease. 'The detrimental increase of abnormal tau is closely associated with heightened inflammatory damage in the brain,' Parhizkar said. 'Research from our lab and others has demonstrated that inflammation in the brain is a significant factor contributing to the brain damage seen in neurodegenerative diseases like Alzheimer's.' 'Consequently, by decreasing both the abnormal buildup of tau and inflammatory damage, lemborexant may be highly effective in safeguarding the brain from these sources of injury,' she added. Additionally, scientists discovered that mice treated with the sleep aid had a 30–40% larger hippocampus volume compared to those not treated with the medication. 'The larger hippocampal volume indicates reduced brain damage and cellular loss in mice treated with lemborexant compared to those given vehicle control,' Holtzman said. 'In the latter group, abnormal tau protein continued to accumulate in the brain, resulting in cell damage, death, and therefore shrinkage of the hippocampus typically observed with neurodegeneration.' MNT also had the opportunity to speak with Gary Small, MD, chair of psychiatry at Hackensack University Medical Center in New Jersey, about this study. Small, who was not involved in the current research, commented that the findings from this new study are consistent with previous research linking restful sleep with better cognitive health. 'For example, my research team found that sleep quality is related to both objective measures of sustained attention and self-awareness of memory decline, suggesting that interventions for improving sleep quality may contribute not only to improving the ability to focus on a particular task but also in reducing memory complaints,' he told us. 'Other work has shown that restful sleep reduces brain amyloid and inflammation, which may explain why sleep benefits cognition. The Washington University team now sheds additional light on an underlying link between insomnia and cognitive impairment: accumulation of tau protein, particularly in brain regions controlling memory,' Small added. 'Nearly 40% of people in the U.S. complain of insomnia, which can lead to daytime fatigue, memory issues, difficulty concentrating, anxiety, depression, irritability, and disrupted work and social activities. Available medicines may lead to dependency and pose such side effects as daytime drowsiness, dizziness, headache, unusual dreams, and memory problems. Finding innovative treatments that reduce tau accumulation in the brain and promote restful sleep would have the dual effect of combating Alzheimer's disease and chronic insomnia' Still, Small cautioned that, while '[t]his study is encouraging […] findings in an animal model must move forward to clinical trials of human volunteers to determine the safety and effectiveness of this potential treatment.' Alzheimer's / Dementia Sleep / Sleep Disorders / Insomnia Drugs
